| Project/Area Number |
24249002
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Okazaki Research Facilities, National Institutes of Natural Sciences (2013-2014)
Nagoya City University (2012) |
|---|
Principal Investigator |
KATO Koichi 大学共同利用機関法人自然科学研究機構(岡崎共通研究施設), 岡崎統合バイオサイエンスセンター, 教授 (20211849)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAGUCHI Takumi 分子科学研究所, 生命・錯体分子科学研究領域, 助教 (60522430)
YAGI Hirokazu 名古屋市立大学, 薬学研究科(研究院), 講師 (70565423)
SATOH Tadashi 名古屋市立大学, 薬学研究科(研究院), 准教授 (80532100)
矢木 真穂 大学共同利用機関法人自然科学研究機構(岡崎共通研究施設), その他部局等, 助教 (40608999)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
YAGI Maho (UTSUMI Maho) 大学共同利用機関法人自然科学研究機構(岡崎共通研究施設), 岡崎統合バイオサイエンスセンター, 特任助教 (40608999)
|
|---|
| Project Period (FY) |
2012-10-31 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥39,260,000 (Direct Cost: ¥30,200,000、Indirect Cost: ¥9,060,000)
Fiscal Year 2014: ¥13,390,000 (Direct Cost: ¥10,300,000、Indirect Cost: ¥3,090,000)
Fiscal Year 2013: ¥13,130,000 (Direct Cost: ¥10,100,000、Indirect Cost: ¥3,030,000)
Fiscal Year 2012: ¥12,740,000 (Direct Cost: ¥9,800,000、Indirect Cost: ¥2,940,000)
|
|---|
| Keywords | 構造生物学 / 糖鎖認識 / 細胞内レクチン / 免疫グロブリンG |
|---|
| Outline of Final Research Achievements |
In this research project, we have elucidated the glycan-mediated mechanisms of biological functions through structural analyses of molecular complexes and thereby provided the groundwork for developing drugs targeting the carbohydrate recognition systems. In particular, we have revealed molecular mechanisms underlying the selective trafficking and degradation in glycoprotein-fate determination in cells. Furthermore, we have established technical basis for structural analyses of antibodies and thereby obtained solution structure information of these glycoproteins produced in various production vehicles, providing valuable insights into development of antibody drugs.
|
